SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-024046
Filing Date
2024-06-17
Accepted
2024-06-17 09:04:23
Documents
17
Period of Report
2024-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56598
2 ex3-1.htm EX-3.1 13234
3 ex10-1.htm EX-10.1 26971
4 ex10-2.htm EX-10.2 36422
5 ex99-1.htm EX-99.1 19024
  Complete submission text file 0001493152-24-024046.txt   356216

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mymd-20240613.xsd EX-101.SCH 3003
7 XBRL LABEL FILE mymd-20240613_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE mymd-20240613_pre.xml EX-101.PRE 22351
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3949
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241047095
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)